Business Context and Reporting Period
Company: LeMaitre Vascular, Inc. (LMAT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A global provider of medical devices and human tissue cryopreservation services used primarily in vascular surgery. The company operates as a single segment, manufacturing products in Burlington, Massachusetts, and selling globally through a direct sales force and distributors.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Sales | $70,382 | $64,232 | $136,933 | $124,103 |
| Gross Profit | $50,764 | $44,974 | $99,160 | $86,394 |
| Gross Margin | 72.1% | 70.0% | 72.4% | 69.6% |
| Operating Income | $20,399 | $16,142 | $38,174 | $28,768 |
| Net Income | $17,050 | $13,779 | $32,729 | $24,790 |
| Diluted EPS | $0.74 | $0.60 | $1.42 | $1.08 |
| Cash & Equivalents | $26,625 | $28,244 | $26,625 | $28,244 |
| Short-term Marketable Securities | $349,615 | $330,876 | $349,615 | $330,876 |
| Convertible Senior Notes (Net) | $169,091 | $168,645 | $169,091 | $168,645 |
Liquidity: Total current assets were $488.3 million against current liabilities of $29.9 million as of June 30, 2026. The company maintains a strong cash position with over $376 million in cash and short-term marketable securities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year for both the quarter and six-month periods. Growth was driven by higher average selling prices, increased unit volumes, and the European launch of the Artegraft product line.
- Margin Expansion: Gross margin improved by 210 basis points (Q2) and 280 basis points (YTD) compared to the prior year, attributed to price increases, favorable product mix, and lower shipping costs.
- Expense Trends:
- Sales & Marketing: Decreased 3% (Q2) and 1% (YTD) due to lower commissions and contest expenses.
- General & Administrative: Increased 7% (Q2) and 11% (YTD) primarily due to higher headcount and wage increases.
- R&D: Increased 37% (Q2) and 17% (YTD), driven by costs associated with transferring allograft tissue processing from Fox River Grove to Burlington and new facility start-up costs.
- Foreign Exchange: A weaker U.S. dollar increased reported sales by approximately $0.4 million in Q2 and $2.4 million YTD compared to 2025.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Initiatives: The company is consolidating manufacturing into Burlington, MA, and transitioning from distributors to direct sales in several countries (e.g., Portugal, Czechia, AndraValvulotome markets).
- Product Portfolio: Biologics represented 55% of worldwide sales in Q2 2026. The company is winding down certain product lines (e.g., Flexcel single-size packs, CardioCel 3D) to simplify the portfolio.
- Capital Allocation: The Board authorized a $100 million share repurchase program in February 2026 (no repurchases made to date). Quarterly dividends were increased to $0.25 per share.
Risks and Contingencies:
- Regulatory Actions: The FDA issued a warning letter in August 2025 regarding the Artegraft facility. A re-inspection in June 2026 identified new observations. Management is implementing corrective actions, but future enforcement actions or sales disruptions remain a risk.
- Product Recalls: A voluntary recall of certain catheters occurred in April 2025 due to packaging seal issues. While the financial impact was deemed immaterial, future recalls could incur significant costs.
- ERP Implementation: The company is rolling out a new Microsoft Dynamics D365 ERP system globally, which may cause temporary fluctuations in financial reporting and internal controls.
Investor Verification Checklist
- Regulatory Status: Verify the current status of the FDA warning letter regarding the Artegraft facility and the timeline for resolving the June 2026 inspection observations.
- Manufacturing Transition: Monitor the progress and cost implications of the allograft tissue processing transfer from Fox River Grove to Burlington, scheduled for completion by end of 2026.
- Convertible Notes: Review the terms of the $172.5 million Convertible Senior Notes due 2030, specifically the conversion rate adjustments triggered by the increased dividend ($0.25/share).
- Product Mix Shifts: Assess the long-term impact of winding down specific product lines (e.g., Elutia distribution agreement termination) on future revenue streams.
- Foreign Exchange Exposure: Evaluate the sensitivity of future earnings to currency fluctuations, given that approximately 45% of sales occur outside the U.S.